XenTech is a Patient-Derived Tumor Xenograft platform

Offering preclinical cancer models and services for translational drug development

To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.

Database access

Search your model into our PDX library

Login :

Password :

> Create an account

Latest news

April 1-5th, 2017 | Washington, USA | AACR Annual Meeting

  XenTech will be attending the 2017 AACR annual meeting in Washington. Come and visit us at booth #343 and poster sessions !   Poster # 3856 : Identification of circulating tumour cells in breast cancer patient-derived xenograft models Session Date and Time: Tuesday Apr 4, 2017 8:00 AM 12:00 PM Poster # 4936 : […]

Company

Contract Research Organization

XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....

Partnerships

Research collaborations

XenTech has several research collaborations with pharmaceutical and biotechnology companies and with academic institutions. XenTech has established key collaborations with clinical centers in France...